Aviva PLC raised its holdings in Allergan PLC. (NYSE:AGN) by 2.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 287,455 shares of the company’s stock after purchasing an additional 6,722 shares during the period. Aviva PLC owned 0.09% of Allergan PLC. worth $69,892,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of AGN. Veritas Asset Management LLP purchased a new position in shares of Allergan PLC. in the first quarter worth about $761,339,000. Iridian Asset Management LLC CT increased its stake in shares of Allergan PLC. by 141.3% in the first quarter. Iridian Asset Management LLC CT now owns 1,283,833 shares of the company’s stock worth $306,733,000 after purchasing an additional 751,848 shares in the last quarter. Renaissance Technologies LLC purchased a new position in shares of Allergan PLC. in the first quarter worth about $124,255,000. Blue Ridge Capital L.L.C. increased its stake in shares of Allergan PLC. by 24.1% in the first quarter. Blue Ridge Capital L.L.C. now owns 1,909,900 shares of the company’s stock worth $456,313,000 after purchasing an additional 370,400 shares in the last quarter. Finally, Harbour Capital Advisors LLC increased its stake in shares of Allergan PLC. by 21,412.3% in the second quarter. Harbour Capital Advisors LLC now owns 345,917 shares of the company’s stock worth $1,423,000 after purchasing an additional 344,309 shares in the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Several research firms have recently weighed in on AGN. Vetr upgraded shares of Allergan PLC. from a “sell” rating to a “hold” rating and set a $242.88 target price for the company in a research note on Monday, June 26th. Wells Fargo & Company reaffirmed an “outperform” rating and set a $280.00 price objective (up previously from $270.00) on shares of Allergan PLC. in a research note on Wednesday, August 9th. UBS AG reaffirmed an “outperform” rating and set a $275.00 price objective on shares of Allergan PLC. in a research note on Wednesday, August 9th. Royal Bank Of Canada set a $284.00 price objective on shares of Allergan PLC. and gave the company a “buy” rating in a research note on Sunday, July 16th. Finally, Deutsche Bank AG reaffirmed a “buy” rating and set a $273.00 price objective (up previously from $265.00) on shares of Allergan PLC. in a research note on Monday, July 17th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and fifteen have issued a buy rating to the stock. Allergan PLC. has a consensus rating of “Buy” and a consensus target price of $274.69.

Shares of Allergan PLC. (NYSE:AGN) opened at 226.47 on Thursday. The stock has a 50 day moving average of $234.45 and a 200-day moving average of $236.94. Allergan PLC. has a one year low of $184.50 and a one year high of $256.80. The company has a market capitalization of $75.71 billion, a price-to-earnings ratio of 6.90 and a beta of 1.18.

Allergan PLC. (NYSE:AGN) last announced its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.95 by $0.07. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The business had revenue of $4.01 billion during the quarter, compared to analyst estimates of $3.95 billion. During the same period last year, the firm posted $3.35 EPS. The company’s revenue was up 8.8% on a year-over-year basis. On average, equities analysts expect that Allergan PLC. will post $16.25 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Shareholders of record on Friday, August 18th will be issued a dividend of $0.70 per share. This represents a $2.80 dividend on an annualized basis and a yield of 1.24%. The ex-dividend date is Wednesday, August 16th. Allergan PLC.’s dividend payout ratio (DPR) is currently 9.95%.

TRADEMARK VIOLATION NOTICE: This piece of content was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/14/aviva-plc-acquires-6722-shares-of-allergan-plc-agn.html.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Stock Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related stocks with our FREE daily email newsletter.